Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGR-1202 in Relapsed/Refractory Follicular Lymphoma
NCT03178201Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Aug 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbralisib in follicular lymphoma (FL), sponsored by Columbia University. Primary endpoint: Overall Response Rate up to 3 years. Started Aug 2017; status: terminated.
02
Drugs
umbralisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03178201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178201.